Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
7 Dividend Stocks to Buy Now: June 2024
01:38pm, Sunday, 23'rd Jun 2024
Income-oriented investors love finding dividend stocks to buy now. That's particularly true when those stocks are on sale, as many continue to be.
Gilead Records Positive Phase III Results In HIV
03:56am, Saturday, 22'nd Jun 2024
Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revoluti
GILD Stock Today: Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
03:43pm, Friday, 21'st Jun 2024
Support for Gilead shares sits near 57.
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
10:20am, Friday, 21'st Jun 2024
Gilead's (GILD) twice-yearly, subcutaneous lenacapavir has demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy. Shares gain.
Gilead Sciences Stock Surges on HIV Treatment Trial Success
09:18am, Friday, 21'st Jun 2024
Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its P
Defying the Norms: 3 High P/E Stocks With Room to Run
08:45am, Friday, 21'st Jun 2024
One method of identifying which stocks to buy is to find those with price-to-earnings (P/E) ratios below their industry peers or historical averages. A low P/E suggests the stock possesses underlying
Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?
07:35am, Friday, 21'st Jun 2024
Gilead (GILD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
Gilead Stock Surges on Strong Results in HIV Drug Study
04:55pm, Thursday, 20'th Jun 2024
Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in wome
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trial
03:51pm, Thursday, 20'th Jun 2024
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm unveiled new data from a late-stage PURPOSE trial which showed its twice-yearly injectable HIV therap
2 Pharma Stocks Moving in Different Directions Today
01:43pm, Thursday, 20'th Jun 2024
Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
12:31pm, Thursday, 20'th Jun 2024
Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.
Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial
11:22am, Thursday, 20'th Jun 2024
Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Thursday, 20'th Jun 2024
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead's HIV prevention treatment found 100% effective in late-stage trial
09:45am, Thursday, 20'th Jun 2024
Gilead Sciences Inc.'s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
Gilead's long-acting HIV drug superior to daily pill Truvada in study
09:09am, Thursday, 20'th Jun 2024
Gilead Sciences said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truva
